; Whereas Gavi is collaborating with the Global Polio Eradication Initiative on the final push to end polio, and expanding the integration of the inactivated polio vaccine into routine immunization programs; Whereas Gavi has made significant progress in supporting the development and stockpiling of effective vaccines to combat cholera, measles, meningococcal, yellow fever, and Ebola, which could also protect Americans in the event of an outbreak on United States soil; Whereas malaria is one of most long-standing and deadliest diseases in Africa, and in 2022, malaria killed an estimated 580,000 children in Africa, 78 percent of whom were children under five; Whereas Gavi has begun deliveries of new malaria vaccines and will expand the program to dozens of countries as vaccine supply becomes available; Whereas Gavi recently allocated 18,000,000 doses of the malaria vaccine RTS,S in 2023 and 2024, the World Health Organization estimates that at least 40,000,000 to 60,000,000 doses will be needed annually by 2026 and 80,000,000 to 100,000,000 doses will be needed by 2030; Whereas Gavi is supporting expanded procurement, access, and implementation of new malaria vaccine programs to help meet rising demand; Whereas data from malaria vaccine trials indicate that these vaccines can save one life for every 200 children vaccinated, with the potential for significantly impacting public health and saving tens of thousands of lives annually; Whereas Gavi supports the strengthening of health systems to ensure effective immunization and health services, including through the provision of cold chain equipment that can also be effectively repurposed for emergency response, as was demonstrated during the COVID–19 pandemic; Whereas, through COVAX, Gavi and global partners delivered nearly 2,000,000,000 doses of COVID–19 vaccines to 146 economies, and averted an estimated 2,700,000 deaths in Advance Market Commitment lower-income participating economies